UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%Zacks Investment Research • 10/01/26
Liquidia: Bullish On Their Growth Potential Despite YUTREPIA's Legal Tail RiskSeeking Alpha • 09/30/26
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?Zacks Investment Research • 09/11/26
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?Zacks Investment Research • 09/10/26
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic SclerosisGlobeNewsWire • 09/03/26
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 CongressGlobeNewsWire • 09/02/26
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare ConferenceGlobeNewsWire • 09/01/26
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?Zacks Investment Research • 08/27/26
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?Zacks Investment Research • 08/17/26
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue PathZacks Investment Research • 08/13/26
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins FollowSeeking Alpha • 08/13/26